Product image of Navirel (Vinorelbine) supplied by GNH India

Navirel

Active Ingredient:
Vinorelbine
Origin:
EU

Navirel (Vinorelbine)

Vinorelbine, the active ingredient in Navirel, is a Vinca alkaloid presented as an injectable solution for intravenous use. It is employed in the treatment of certain solid tumors, primarily non‑small cell lung cancer and breast cancer, in adult patients.

GNH India supplies Navirel as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory support for import and distribution. Clients benefit from reliable logistics, temperature‑controlled shipping where required, and comprehensive documentation.

Manufacturer / TM Owner

Medac Gesellschaft Für Klinische Spezialpräparate Mbh (Wedel)

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Vinorelbine is used in oncology to target rapidly dividing cancer cells, particularly in solid tumours.

  • Non‑small cell lung cancer: administered to inhibit tumour growth in advanced disease.
  • Breast cancer: used as part of combination chemotherapy for metastatic or locally advanced disease.
  • Advanced solid tumours (off‑label clinical trials): may be evaluated where standard options are limited.

How It Works

  • Vinorelbine binds to tubulin dimers, preventing their polymerisation into microtubules. This disruption blocks the formation of the mitotic spindle, leading to cell‑cycle arrest in the M‑phase and ultimately causing apoptosis of rapidly dividing cancer cells.

Side Effects

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Neutropenia: reduced neutrophil count increasing infection risk.
  • Nausea and vomiting: gastrointestinal upset common after infusion.
  • Fatigue: persistent tiredness reported by many patients.
  • Alopecia: hair loss affecting scalp and body hair.
  • Constipation: decreased bowel movements post‑treatment.
  • Anemia: lowered red blood cell levels causing weakness.

Serious or Rare Side Effects

  • Febrile neutropenia: fever with low neutrophils requiring urgent care.
  • Pulmonary toxicity: interstitial pneumonitis or fibrosis.
  • Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
  • Cardiac arrhythmias: irregular heart rhythms observed in some patients.
  • Thrombocytopenia: low platelet count leading to bleeding risk.
  • Hepatic dysfunction: elevated liver enzymes indicating liver stress.

Precautions & Warnings

Before initiating therapy with Navirel, clinicians should assess patient suitability and monitor for potential complications.

  • Hematologic monitoring: perform regular complete blood counts to detect neutropenia or anemia.
  • Liver function assessment: evaluate hepatic enzymes and adjust dose in impairment.
  • Infection vigilance: avoid use in patients with active severe infections.
  • Concomitant myelosuppressants: use caution when combined with other bone‑marrow‑suppressing agents.
  • Antiemetic prophylaxis: administer appropriate anti‑nausea medication prior to infusion.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Vinorelbine can interact with several drug classes, influencing efficacy or toxicity.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase vinorelbine exposure.
  • Potent CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels.
  • Concurrent myelosuppressive chemotherapy: heightens risk of severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (e.g., warfarin): monitor coagulation parameters for bleeding risk.
  • Antiemetics containing CYP3A4 substrates (e.g., ondansetron): adjust dosing if needed.
  • Drugs affecting hepatic transporters (e.g., bilirubin‑binding agents): observe liver function tests.

Frequently Asked Questions

Navirel contains the chemotherapeutic agent vinorelbine and is indicated for the treatment of adult patients with non‑small cell lung cancer and breast cancer, typically as part of a multi‑drug chemotherapy regimen aimed at controlling tumour growth.

Vinorelbine interferes with microtubule dynamics by binding to tubulin, preventing polymerisation into functional microtubules. This disruption halts mitotic spindle formation, causing cell‑cycle arrest in the M‑phase and leading to apoptosis of rapidly dividing cancer cells.

The dose of Navirel is individualized by the treating oncologist based on the patient’s body surface area, disease stage, prior therapy and overall health. It is administered intravenously under medical supervision, and the prescribing clinician determines the exact regimen.

Safety of vinorelbine during pregnancy and lactation has not been established. It is generally contraindicated in pregnant or nursing women unless the potential therapeutic benefit justifies the potential risk to the fetus or infant.

To request Navirel, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Vinorelbine belongs to the Vinca alkaloid class, offering a distinct mechanism from taxanes such as paclitaxel. Compared with other vinca agents like vincristine, vinorelbine has a more favourable neurotoxicity profile but a higher incidence of myelosuppression, making choice dependent on tumour type and patient tolerance.

Navirel should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to administration, the solution should be inspected for particulate matter and used within the time frame specified by the manufacturer.

Navirel is administered by intravenous infusion, usually over 6–10 minutes, under the supervision of qualified healthcare professionals. The infusion rate and total dose are determined by the prescribing physician based on the patient’s clinical parameters.

The most critical adverse events include severe neutropenia or febrile neutropenia, pulmonary toxicity such as interstitial pneumonitis, serious hypersensitivity reactions, and significant hepatic dysfunction. Prompt medical evaluation is required if symptoms such as fever, shortness of breath, rash or jaundice develop.

Navirel is contraindicated in patients with pre‑existing severe bone‑marrow suppression, uncontrolled active infections, known hypersensitivity to vinorelbine or other Vinca alkaloids, and in those for whom the risk‑benefit assessment does not support its use, such as certain pregnant or lactating women.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Vinorelbine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT